glp-1 news today 2025 november trends 2025: real-world data, patient outcomes & future therapies glp-1 weight loss drug news

As healthcare professionals, we should remember that obesity is a chronic, relapsing metabolic disease, not simply a consequence of lifestyle choices

Experimental evidence is ongoing to explore and unravel all these possible beneficial mechanisms, while the combination of both drug categories (at least in patients with T2D) with or without other therapeutic strategies seems promising

Kidney function should be monitored in individuals with pre-existing kidney disease

Key Takeaways Glucagon-like peptide-1 (GLP-1) drugs, like Ozempic and Wegovy, may slow Alzheimers progression

They can be managed, however, andeven betterfade on their own eventually for most people